3 articles
How PARP inhibitors exploit BRCA deficiency to selectively kill cancer cells.
Combination BRAF and MEK inhibitors have improved survival in BRAF-mutant melanoma.
KRAS was once considered undruggable; now targeted inhibitors are approved.
